問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberNP25620

2011-11-01 - 2013-12-31

Phase II

Terminated3

ICD-10F34.1

Dysthymic disorder

ICD-9300.4

Neurotic depression

A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response

  • Trial Applicant

  • Sponsor

    Roche

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2025/08/20

Investigators and Locations

Principal Investigator Hsien-Yuan Lane Division of Psychiatry

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Ya-Mei Bai Division of Psychiatry

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 王亮人 Division of Psychiatry

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Condition/Disease

Major depressive disorder

Objectives

To realize the safety and efficacy of RO4917523 in patients with major depressive disorder with inadequate response

Test Drug

RO4917523

Active Ingredient

RO4917523

Dosage Form

Capsule

Dosage

0.5/1.5

Endpoints

MADRS

Inclution Criteria

None

Exclusion Criteria

No

The Estimated Number of Participants

  • Taiwan

    30 participants

  • Global

    318 participants